Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii

Qi Weng; Feng Zhang; Quan Zheng

doi:10.1002/mco2.696

MedComm ›› 2024, Vol. 5 ›› Issue (8) : e696 DOI: 10.1002/mco2.696

HIGHLIGHT

Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii

Qi Weng ¹
, Feng Zhang ²^,^†
, Quan Zheng ²^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Qi Weng, Feng Zhang, Quan Zheng. Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii. MedComm, 2024, 5(8): e696 DOI:10.1002/mco2.696

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zampaloni C, Mattei P, Bleicher K, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024; 625: 566-571.

[2]	Pahil KS, Gilman MSA, Baidin V, et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature. 2024; 625: 572-577.

[3]	CDC. Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, CDC; 2019.

[4]

Guenther A, Millar L, Messer A, et al. 2126. Safety, tolerability, and pharmacokinetics (PK) in healthy participants following single dose administration of zosurabalpin, a novel pathogen-specific antibiotic for the treatment of serious Acinetobacter infections. Open Forum Infect Dis. 2023; 10(2): ofad500.1749.

[5]	Owens TW, Taylor RJ, Pahil KS, et al. Structural basis of unidirectional export of lipopolysaccharide to the cell surface. Nature. 2019; 567: 550-553.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.